Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Anaplastic thyroid cancers are rare, aggressive tumors. Standard treatment options include
surgery and chemoradiation. Few treatment options are available once metastases develop.
Recent data suggest that Imatinib (Gleevec) may be advantageous in this patient population.
Patients who have been treated for anaplastic thyroid cancer with chemoradiation or surgery
who develop recurrent or metastatic disease outside of the field of radiation are eligible.
Patients will be treated with Imatinib 400 mg two times a day for eight weeks, followed by
radiologic assessment. Patients will be treated until disease progression or a complete
response is obtained.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center